FY2025 EPS Estimates for Exelixis Increased by William Blair

Exelixis, Inc. (NASDAQ:EXEL) – Investment analysts at William Blair increased their FY2025 earnings per share estimates for Exelixis in a report released on Sunday, January 12th. William Blair analyst A. Hsieh now expects that the biotechnology company will earn $1.69 per share for the year, up from their previous estimate of $1.44. The consensus estimate for Exelixis’ current full-year earnings is $1.69 per share.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company had revenue of $539.50 million for the quarter, compared to analyst estimates of $490.31 million. During the same quarter in the prior year, the company earned $0.10 EPS. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year.

A number of other equities analysts have also weighed in on the company. Truist Financial upped their target price on Exelixis from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday. Brookline Capital Management started coverage on shares of Exelixis in a research note on Monday, December 23rd. They issued a “buy” rating on the stock. BMO Capital Markets downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $36.00 to $40.00 in a research report on Friday, December 20th. Stephens upped their target price on shares of Exelixis from $23.00 to $29.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 30th. Finally, Morgan Stanley lifted their price target on Exelixis from $26.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, October 11th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $34.75.

Exelixis Trading Up 4.5 %

Shares of NASDAQ EXEL opened at $37.27 on Wednesday. The firm has a market capitalization of $10.64 billion, a P/E ratio of 23.89, a P/E/G ratio of 0.88 and a beta of 0.53. The firm’s 50-day moving average price is $34.92 and its 200-day moving average price is $29.08. Exelixis has a 1-year low of $20.01 and a 1-year high of $37.31.

Insider Buying and Selling

In other news, EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $28.39, for a total value of $709,750.00. Following the transaction, the executive vice president now owns 580,325 shares of the company’s stock, valued at approximately $16,475,426.75. The trade was a 4.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director George Poste sold 30,000 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $34.00, for a total transaction of $1,020,000.00. Following the transaction, the director now directly owns 169,020 shares of the company’s stock, valued at $5,746,680. This trade represents a 15.07 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 314,736 shares of company stock valued at $10,849,110. Company insiders own 2.85% of the company’s stock.

Institutional Investors Weigh In On Exelixis

Hedge funds and other institutional investors have recently made changes to their positions in the company. USA Financial Formulas purchased a new stake in shares of Exelixis in the fourth quarter worth approximately $32,000. V Square Quantitative Management LLC bought a new position in Exelixis in the 3rd quarter valued at $30,000. Brooklyn Investment Group purchased a new stake in Exelixis in the third quarter worth $42,000. Capital Performance Advisors LLP bought a new stake in shares of Exelixis during the third quarter worth $61,000. Finally, Essex Investment Management Co. LLC purchased a new stake in shares of Exelixis during the third quarter valued at $74,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.